Jump to content
RemedySpot.com

Whistleblower in Coventry: Dr Yolande Lucire and Big Pharma - Australia

Rate this topic


Recommended Posts

Posted

http://www.onlineopinion.com.au/view.asp?article=11394 & page=0

Whistleblower in Coventry: Dr Yolande Lucire and Big Pharma

By King - posted Monday, 20

December 2010

Australia lags well behind the US and Britain in facing up to

the malfeasance of multinational drug companies pushing unsafe

products. Very often Big Pharma itself has largely conjured up

the booming markets in which its dubious drugs offer expensive

treatment for dubious medical conditions.

The biggest and most lucrative scandals have been in two types

of second-generation drugs: anti-depressants or SSRIs - Prozac,

Paxil, Zoloft, etc, and "atypical" antipsychotics such as

Zyprexa, Risperdal and Seroquel which were known from their

licensing to be ineffective for the vast majority of clinical

trial subjects and up to twice as bad for inducing suicide as

antidepressants.

The corrupt drug trial and marketing practices of Big Pharma

include imaginary science (the serotonin deficiency theory of

depression), systematic suppression of lethal side effects

(akathisia - cannot-sit-down restlessness - leading to suicidal

ideation, suicide and murder) and a multi-billion dollar success

over the past generation in medicalising the ordinary ups and

downs of the human psyche.

Feeling sad? ("Moderate depression", worthy of a happy little

Zoloft rock.) Diffident? ("Social anxiety disorder", try

Aropax.) If antidepressants cured any significant number of

people there would be significantly less cost and less demand

for mental health services in Australia. Whether from inadequate

or tendentious pharmacology training, laziness, busyness, greed

driven by willed ignorance or even misplaced conviction, the

medical profession has succumbed to the cynical marketing and

the targeted blandishments of the pharmaceutical companies.

Medical and scientific journals from Nature to The

New England Journal of Medicine allowed their columns to

be infiltrated for years by blatantly dishonest research

reporting and ghost written articles commissioned in Pharma-land

but signed by distinguished professors frequently in receipt of

seven-figure research and consultancy funding. Most of these

journals do now take another tack, debunking Pharma claims and

exposing fraudulence. But many medical professional bodies are

still being subsidised beyond hope of objective dealing with the

issue of mass iatrogenesis caused by dud drugs andmultiple drug

prescribing ("polypharmacy"), and particularly with the lethal

side effects of anti-depressants.

The key drug regulator in the US - and the planet - the United

States Food and Drug Administration (US FDA) has failed to purge

the Pharma-friendly experts who have dominated its rulings up to

now. Our own Therapeutic Goods Administration obediently follows

suit, also licensing drugs largely on information provided by

their makers. But in America the going has been getting

perceptibly harder for the drug companies.

Whistleblowers, class actions and litigious state governments

confronting ballooning health costs have been taking a toll on

profits. Pfizer was recently fined $US2.3 billion for

fraudulently promoting four drugs including the "antipsychotic"

Zeldox last year. This fine is seriously denting Pfizer's bottom

(net income) line of $US8 billion, and whistleblowers, including

former Pfizer employees, collected over $US100 million for their

pains in this case - a big threat to Pharma for the future.

Although such a fine has been described in a recent British

Medical Journal as"firing 22s into the arse of a rhino"

and Pfizer has been called "too big to nail" (only a Pfizer

subsidiary pleaded guilty to criminal charges), drug companies

face a rising tide of multi-billion dollar class actions and the

prospect of new laws which could put them out of business. The

original whistleblowers who were listened to have made the key

difference in the United States. Whitaker traced the

suicide epidemic and mental health cost blow-out following the

launch of Prozac in 1988. The quiet Irishman, Healy,

exposed drug trial fakery and the vast, hidden collateral damage

of pharma's SSRI bonanza in the 1990s and later.

These two and others have engineered a paradigm shift in public

understanding, and professorial heads in receipt of undeclared

consultancy riches have started to roll at research institutes

and universities in the US, including even Harvard. According to

the New York Times, Dr ph Biederman, the pioneer of

"aggressive diagnosis and drug treatment of childhood bipolar

disorder", failed

to report most of the $1.6 million he received in pharma

funding over several years while at Harvard.

The single person who has been trying hardest to fill the

Whitaker/Healy whistleblower gap in Australia is Sydney

psychiatrist, Dr Yolande Lucire. Thirteen years ago she began to

notice alarmingly high hospital admission and suicide rates

among patients treated with SSRIs and atypical antipsychotics in

New South Wales's Greater Southern Area Health Service. Since

then she has been fighting back against the Pharma-driven

psychiatric consensus that treating with SSRIs is safe and

effective, working hard to wean patient-victims as well as their

prescribers off the drugs.

She has steadily accumulated damning statistics on suicide,

homicide and hospitalisation rates among these patients in New

South Wales. More recently it has become clear that a large

percentage of people being treated with antidepressants can't

metabolise them due to common genetic mutations. Dr Lucire has

been campaigning to introduce systematic doctor education in

order to minimise promiscuous and uninformed anti-depressant

prescribing. With her complaints, findings and warnings about

lack of action, Dr Lucire has been assiduously lobbying her

colleagues, the Medical Board and the Health Care Complaints

Commission of NSW, the Adverse Drug Reactions Advisory Committee

(ADRAC) of the federal Therapeutic Goods Administration and a

clutch of ministers, both state and federal, for many years.

Most recently she has been providing redacted files on her own

extensive sample of DNA swab-tested relapsing patients suffering

from the side effects of SSRIs and polypharmacy.

And she has had one notable victory in the political arena.

Under pressure from Dr Lucire, the secretary of Health and

Ageing set up an inquiry early in 2009 into 90 of her serious

adverse drug reaction reports, which occurred mainly in normal

folk treated for stress and other vicissitudes of life and who

had become suicidal and/or homicidal on antidepressants. The

Psychiatric Drug Safety Expert Advisory Panel reported in

December last year, confirming her concerns about the

near-universality of ignorant polypharmacy and dangerous

gene-based drug-drug interactions leading to akathisia, suicide

and homicide and all the mental states preceding them.But its

recommendations are still waiting to be noticed by the NSW

Medical Board and Department of Health.

So far the Medical Board seems to have quite other ideas about

Dr Lucire's contribution to public health than the Advisory

Panel. In July 2007 one of the many patients she was trying to

save from another bout of potentially lethal akathisia killed

her own father and sister. In her view, this patient's akathisia

was initially caused by the polypharmacy which had previously

aggravated her mental condition. But this case led to Medical

Board proceedings against her. She has concerns about the

board's procedures and why she is being targeted.

At the core of her alleged delinquency are charges that she has

failed to recognise that SSRI treatment is "standard practice" -

also "best practice"; that she has "unusual beliefs (read: not

good for the professional bottom line) about the side effects of

psychotropic medication"; that she is "lacking in respect for

colleagues' diagnoses", and has been "guilty of destroying

patients" confidence in their treating doctor" (while saving

their sanity and/or lives, could we add?).

Galileo would have been familiar with this kind of stuff. What

Dr Lucire's hostile critics, like Galileo's, have not done is

respond professionally to her criticisms in scientific terms.

Could they be scared of the result? Dr Lucire continues to draw

attention to the causes of the public mental health problem,

albeit at times in a naive, didactic or exasperated manner, as

she admits herself. She has good grounds for paranoia, but she

is unwise to be forever saying that no-one takes any notice of

her (fully justified) Cassandra-like warnings. The Expert

Advisory Panel did; some fair-minded journalists do, and also a

sprinkling of academics in science based disciplines.

She is appealing the latest tribunal decision in the Supreme

Court of New South Wales backed with character references by a

Who's Who of people wise to the ways of corporate money in the

medical professions and familiar with the differences between

majority views and what is scientifically established in

psychiatry. Dr Lucire also persists in trying to stymie the

campaign currently building around the country to drastically

expand hospital and clinical services for the mentally ill.

Prominent in this campaign are Australian of the Year 2010,

Professor McGorry of Melbourne University and headspace,

and Professor Ian Hickie of the Brain and Mind Research

Institute at Sydney University and the SPHERE national

depression initiative.

McGorry is a proponent of early drug intervention to

combat youth depression. Ian Hickie is an outspoken and

genuinely concerned intervener in a wide array of debates on the

social health of Australia and Australians, most recently

concerning the fate of badly accommodated university students.

But his Brain and Mind Institute was lately discovered by The

Australian to be housing

Lifeblood, a private company helping the pharmacy

industry spend $75 million on "doctors' education". Lifeblood

has boasted on its website that SPHERE, "a mental health program

undertaken by 12,000 GPs since 1998", of which both Pfizer and

the Brain and Mind Research Institute are commercial partners,

has restored Pfizer's Zoloft to market leadership in the

anti-depressant stakes. Hickie himself was the architect of the

controversial (and Bristol Myers Squibb funded) "depression

screening tool" (a checklist of questions for GPs) used in

SPHERE.

How awkward this all must be for his institute - and for your

(and my) Sydney University, which also boasts a Pfizer/PPF Chair

of Pharmacy Management and a Pfizer Australian Chair in Clinical

Pharmacy. Professor Hickie also co-authored the Royal Australian

and New Zealand College of Psychiatrists' original (2003)

recommended guidelines for treatment of depression, whose

clarion call was: "Depression is common, serious and treatable.

It affects 1 in 25 people in any 1 month." These RANZCP

guidelines recommended that even "moderately severe" depression

should be treated with Nefazadone, a drug which was withdrawn

four months later because of fatal side effects. Very few

specific side effects or drug-drug interactions were reported in

these guidelines, which have been only cosmetically improved in

their 2009 version for the “consumer and carer”.

The RANZCP guidelines (and near identical ones around the

world) emerged from the Texas of Governor W Bush where

they became mandatory in the treatment of prisoners and public

mental patients following a lavish lobbying campaign under the

rubric of the Texas Medication Algorithm Project by Big Pharma.

According to Dr Lucire, the notion of applying algorithms or

"one size fits all" to a genetically diverse population in the

days of personalised medicine borders on obscene.

What is first and most needed in Australia's so far depressing,

big American, Pharma driven approach to depression is not more

of the same but less. Antidepressants used for anything less

then severe depression, and closely monitored, are an expensive,

ineffective (less than three per cent more effective than

placebo in clinical trials presented to the US Food and Drug

Administration for their licensing) and dangerous family of

drugs whose side effects and addictive qualities have triggered

a serious crisis in public health - not least by an explosion of

hospital beds for unrecognised side effect casualties.

The highway to massive cost savings - and effective redirection

of public spending on mental health - is to break the addiction

of psychiatrists, doctors, medical bureaucracies and patients to

the notion that there is a pill for every ill. Dr Lucire's

professional martyrdom may well continue short term. But

developments in the US suggest that her brave and brilliant

efforts in this direction, however casually and cynically

denigrated, will eventually prevail here. There will be many and

much to answer for if justice for her and the Australian victims

of the SSRI scourge is long delayed.

Posted

http://www.onlineopinion.com.au/view.asp?article=11394 & page=0

Whistleblower in Coventry: Dr Yolande Lucire and Big Pharma

By King - posted Monday, 20

December 2010

Australia lags well behind the US and Britain in facing up to

the malfeasance of multinational drug companies pushing unsafe

products. Very often Big Pharma itself has largely conjured up

the booming markets in which its dubious drugs offer expensive

treatment for dubious medical conditions.

The biggest and most lucrative scandals have been in two types

of second-generation drugs: anti-depressants or SSRIs - Prozac,

Paxil, Zoloft, etc, and "atypical" antipsychotics such as

Zyprexa, Risperdal and Seroquel which were known from their

licensing to be ineffective for the vast majority of clinical

trial subjects and up to twice as bad for inducing suicide as

antidepressants.

The corrupt drug trial and marketing practices of Big Pharma

include imaginary science (the serotonin deficiency theory of

depression), systematic suppression of lethal side effects

(akathisia - cannot-sit-down restlessness - leading to suicidal

ideation, suicide and murder) and a multi-billion dollar success

over the past generation in medicalising the ordinary ups and

downs of the human psyche.

Feeling sad? ("Moderate depression", worthy of a happy little

Zoloft rock.) Diffident? ("Social anxiety disorder", try

Aropax.) If antidepressants cured any significant number of

people there would be significantly less cost and less demand

for mental health services in Australia. Whether from inadequate

or tendentious pharmacology training, laziness, busyness, greed

driven by willed ignorance or even misplaced conviction, the

medical profession has succumbed to the cynical marketing and

the targeted blandishments of the pharmaceutical companies.

Medical and scientific journals from Nature to The

New England Journal of Medicine allowed their columns to

be infiltrated for years by blatantly dishonest research

reporting and ghost written articles commissioned in Pharma-land

but signed by distinguished professors frequently in receipt of

seven-figure research and consultancy funding. Most of these

journals do now take another tack, debunking Pharma claims and

exposing fraudulence. But many medical professional bodies are

still being subsidised beyond hope of objective dealing with the

issue of mass iatrogenesis caused by dud drugs andmultiple drug

prescribing ("polypharmacy"), and particularly with the lethal

side effects of anti-depressants.

The key drug regulator in the US - and the planet - the United

States Food and Drug Administration (US FDA) has failed to purge

the Pharma-friendly experts who have dominated its rulings up to

now. Our own Therapeutic Goods Administration obediently follows

suit, also licensing drugs largely on information provided by

their makers. But in America the going has been getting

perceptibly harder for the drug companies.

Whistleblowers, class actions and litigious state governments

confronting ballooning health costs have been taking a toll on

profits. Pfizer was recently fined $US2.3 billion for

fraudulently promoting four drugs including the "antipsychotic"

Zeldox last year. This fine is seriously denting Pfizer's bottom

(net income) line of $US8 billion, and whistleblowers, including

former Pfizer employees, collected over $US100 million for their

pains in this case - a big threat to Pharma for the future.

Although such a fine has been described in a recent British

Medical Journal as"firing 22s into the arse of a rhino"

and Pfizer has been called "too big to nail" (only a Pfizer

subsidiary pleaded guilty to criminal charges), drug companies

face a rising tide of multi-billion dollar class actions and the

prospect of new laws which could put them out of business. The

original whistleblowers who were listened to have made the key

difference in the United States. Whitaker traced the

suicide epidemic and mental health cost blow-out following the

launch of Prozac in 1988. The quiet Irishman, Healy,

exposed drug trial fakery and the vast, hidden collateral damage

of pharma's SSRI bonanza in the 1990s and later.

These two and others have engineered a paradigm shift in public

understanding, and professorial heads in receipt of undeclared

consultancy riches have started to roll at research institutes

and universities in the US, including even Harvard. According to

the New York Times, Dr ph Biederman, the pioneer of

"aggressive diagnosis and drug treatment of childhood bipolar

disorder", failed

to report most of the $1.6 million he received in pharma

funding over several years while at Harvard.

The single person who has been trying hardest to fill the

Whitaker/Healy whistleblower gap in Australia is Sydney

psychiatrist, Dr Yolande Lucire. Thirteen years ago she began to

notice alarmingly high hospital admission and suicide rates

among patients treated with SSRIs and atypical antipsychotics in

New South Wales's Greater Southern Area Health Service. Since

then she has been fighting back against the Pharma-driven

psychiatric consensus that treating with SSRIs is safe and

effective, working hard to wean patient-victims as well as their

prescribers off the drugs.

She has steadily accumulated damning statistics on suicide,

homicide and hospitalisation rates among these patients in New

South Wales. More recently it has become clear that a large

percentage of people being treated with antidepressants can't

metabolise them due to common genetic mutations. Dr Lucire has

been campaigning to introduce systematic doctor education in

order to minimise promiscuous and uninformed anti-depressant

prescribing. With her complaints, findings and warnings about

lack of action, Dr Lucire has been assiduously lobbying her

colleagues, the Medical Board and the Health Care Complaints

Commission of NSW, the Adverse Drug Reactions Advisory Committee

(ADRAC) of the federal Therapeutic Goods Administration and a

clutch of ministers, both state and federal, for many years.

Most recently she has been providing redacted files on her own

extensive sample of DNA swab-tested relapsing patients suffering

from the side effects of SSRIs and polypharmacy.

And she has had one notable victory in the political arena.

Under pressure from Dr Lucire, the secretary of Health and

Ageing set up an inquiry early in 2009 into 90 of her serious

adverse drug reaction reports, which occurred mainly in normal

folk treated for stress and other vicissitudes of life and who

had become suicidal and/or homicidal on antidepressants. The

Psychiatric Drug Safety Expert Advisory Panel reported in

December last year, confirming her concerns about the

near-universality of ignorant polypharmacy and dangerous

gene-based drug-drug interactions leading to akathisia, suicide

and homicide and all the mental states preceding them.But its

recommendations are still waiting to be noticed by the NSW

Medical Board and Department of Health.

So far the Medical Board seems to have quite other ideas about

Dr Lucire's contribution to public health than the Advisory

Panel. In July 2007 one of the many patients she was trying to

save from another bout of potentially lethal akathisia killed

her own father and sister. In her view, this patient's akathisia

was initially caused by the polypharmacy which had previously

aggravated her mental condition. But this case led to Medical

Board proceedings against her. She has concerns about the

board's procedures and why she is being targeted.

At the core of her alleged delinquency are charges that she has

failed to recognise that SSRI treatment is "standard practice" -

also "best practice"; that she has "unusual beliefs (read: not

good for the professional bottom line) about the side effects of

psychotropic medication"; that she is "lacking in respect for

colleagues' diagnoses", and has been "guilty of destroying

patients" confidence in their treating doctor" (while saving

their sanity and/or lives, could we add?).

Galileo would have been familiar with this kind of stuff. What

Dr Lucire's hostile critics, like Galileo's, have not done is

respond professionally to her criticisms in scientific terms.

Could they be scared of the result? Dr Lucire continues to draw

attention to the causes of the public mental health problem,

albeit at times in a naive, didactic or exasperated manner, as

she admits herself. She has good grounds for paranoia, but she

is unwise to be forever saying that no-one takes any notice of

her (fully justified) Cassandra-like warnings. The Expert

Advisory Panel did; some fair-minded journalists do, and also a

sprinkling of academics in science based disciplines.

She is appealing the latest tribunal decision in the Supreme

Court of New South Wales backed with character references by a

Who's Who of people wise to the ways of corporate money in the

medical professions and familiar with the differences between

majority views and what is scientifically established in

psychiatry. Dr Lucire also persists in trying to stymie the

campaign currently building around the country to drastically

expand hospital and clinical services for the mentally ill.

Prominent in this campaign are Australian of the Year 2010,

Professor McGorry of Melbourne University and headspace,

and Professor Ian Hickie of the Brain and Mind Research

Institute at Sydney University and the SPHERE national

depression initiative.

McGorry is a proponent of early drug intervention to

combat youth depression. Ian Hickie is an outspoken and

genuinely concerned intervener in a wide array of debates on the

social health of Australia and Australians, most recently

concerning the fate of badly accommodated university students.

But his Brain and Mind Institute was lately discovered by The

Australian to be housing

Lifeblood, a private company helping the pharmacy

industry spend $75 million on "doctors' education". Lifeblood

has boasted on its website that SPHERE, "a mental health program

undertaken by 12,000 GPs since 1998", of which both Pfizer and

the Brain and Mind Research Institute are commercial partners,

has restored Pfizer's Zoloft to market leadership in the

anti-depressant stakes. Hickie himself was the architect of the

controversial (and Bristol Myers Squibb funded) "depression

screening tool" (a checklist of questions for GPs) used in

SPHERE.

How awkward this all must be for his institute - and for your

(and my) Sydney University, which also boasts a Pfizer/PPF Chair

of Pharmacy Management and a Pfizer Australian Chair in Clinical

Pharmacy. Professor Hickie also co-authored the Royal Australian

and New Zealand College of Psychiatrists' original (2003)

recommended guidelines for treatment of depression, whose

clarion call was: "Depression is common, serious and treatable.

It affects 1 in 25 people in any 1 month." These RANZCP

guidelines recommended that even "moderately severe" depression

should be treated with Nefazadone, a drug which was withdrawn

four months later because of fatal side effects. Very few

specific side effects or drug-drug interactions were reported in

these guidelines, which have been only cosmetically improved in

their 2009 version for the “consumer and carer”.

The RANZCP guidelines (and near identical ones around the

world) emerged from the Texas of Governor W Bush where

they became mandatory in the treatment of prisoners and public

mental patients following a lavish lobbying campaign under the

rubric of the Texas Medication Algorithm Project by Big Pharma.

According to Dr Lucire, the notion of applying algorithms or

"one size fits all" to a genetically diverse population in the

days of personalised medicine borders on obscene.

What is first and most needed in Australia's so far depressing,

big American, Pharma driven approach to depression is not more

of the same but less. Antidepressants used for anything less

then severe depression, and closely monitored, are an expensive,

ineffective (less than three per cent more effective than

placebo in clinical trials presented to the US Food and Drug

Administration for their licensing) and dangerous family of

drugs whose side effects and addictive qualities have triggered

a serious crisis in public health - not least by an explosion of

hospital beds for unrecognised side effect casualties.

The highway to massive cost savings - and effective redirection

of public spending on mental health - is to break the addiction

of psychiatrists, doctors, medical bureaucracies and patients to

the notion that there is a pill for every ill. Dr Lucire's

professional martyrdom may well continue short term. But

developments in the US suggest that her brave and brilliant

efforts in this direction, however casually and cynically

denigrated, will eventually prevail here. There will be many and

much to answer for if justice for her and the Australian victims

of the SSRI scourge is long delayed.

Posted

http://www.onlineopinion.com.au/view.asp?article=11394 & page=0

Whistleblower in Coventry: Dr Yolande Lucire and Big Pharma

By King - posted Monday, 20

December 2010

Australia lags well behind the US and Britain in facing up to

the malfeasance of multinational drug companies pushing unsafe

products. Very often Big Pharma itself has largely conjured up

the booming markets in which its dubious drugs offer expensive

treatment for dubious medical conditions.

The biggest and most lucrative scandals have been in two types

of second-generation drugs: anti-depressants or SSRIs - Prozac,

Paxil, Zoloft, etc, and "atypical" antipsychotics such as

Zyprexa, Risperdal and Seroquel which were known from their

licensing to be ineffective for the vast majority of clinical

trial subjects and up to twice as bad for inducing suicide as

antidepressants.

The corrupt drug trial and marketing practices of Big Pharma

include imaginary science (the serotonin deficiency theory of

depression), systematic suppression of lethal side effects

(akathisia - cannot-sit-down restlessness - leading to suicidal

ideation, suicide and murder) and a multi-billion dollar success

over the past generation in medicalising the ordinary ups and

downs of the human psyche.

Feeling sad? ("Moderate depression", worthy of a happy little

Zoloft rock.) Diffident? ("Social anxiety disorder", try

Aropax.) If antidepressants cured any significant number of

people there would be significantly less cost and less demand

for mental health services in Australia. Whether from inadequate

or tendentious pharmacology training, laziness, busyness, greed

driven by willed ignorance or even misplaced conviction, the

medical profession has succumbed to the cynical marketing and

the targeted blandishments of the pharmaceutical companies.

Medical and scientific journals from Nature to The

New England Journal of Medicine allowed their columns to

be infiltrated for years by blatantly dishonest research

reporting and ghost written articles commissioned in Pharma-land

but signed by distinguished professors frequently in receipt of

seven-figure research and consultancy funding. Most of these

journals do now take another tack, debunking Pharma claims and

exposing fraudulence. But many medical professional bodies are

still being subsidised beyond hope of objective dealing with the

issue of mass iatrogenesis caused by dud drugs andmultiple drug

prescribing ("polypharmacy"), and particularly with the lethal

side effects of anti-depressants.

The key drug regulator in the US - and the planet - the United

States Food and Drug Administration (US FDA) has failed to purge

the Pharma-friendly experts who have dominated its rulings up to

now. Our own Therapeutic Goods Administration obediently follows

suit, also licensing drugs largely on information provided by

their makers. But in America the going has been getting

perceptibly harder for the drug companies.

Whistleblowers, class actions and litigious state governments

confronting ballooning health costs have been taking a toll on

profits. Pfizer was recently fined $US2.3 billion for

fraudulently promoting four drugs including the "antipsychotic"

Zeldox last year. This fine is seriously denting Pfizer's bottom

(net income) line of $US8 billion, and whistleblowers, including

former Pfizer employees, collected over $US100 million for their

pains in this case - a big threat to Pharma for the future.

Although such a fine has been described in a recent British

Medical Journal as"firing 22s into the arse of a rhino"

and Pfizer has been called "too big to nail" (only a Pfizer

subsidiary pleaded guilty to criminal charges), drug companies

face a rising tide of multi-billion dollar class actions and the

prospect of new laws which could put them out of business. The

original whistleblowers who were listened to have made the key

difference in the United States. Whitaker traced the

suicide epidemic and mental health cost blow-out following the

launch of Prozac in 1988. The quiet Irishman, Healy,

exposed drug trial fakery and the vast, hidden collateral damage

of pharma's SSRI bonanza in the 1990s and later.

These two and others have engineered a paradigm shift in public

understanding, and professorial heads in receipt of undeclared

consultancy riches have started to roll at research institutes

and universities in the US, including even Harvard. According to

the New York Times, Dr ph Biederman, the pioneer of

"aggressive diagnosis and drug treatment of childhood bipolar

disorder", failed

to report most of the $1.6 million he received in pharma

funding over several years while at Harvard.

The single person who has been trying hardest to fill the

Whitaker/Healy whistleblower gap in Australia is Sydney

psychiatrist, Dr Yolande Lucire. Thirteen years ago she began to

notice alarmingly high hospital admission and suicide rates

among patients treated with SSRIs and atypical antipsychotics in

New South Wales's Greater Southern Area Health Service. Since

then she has been fighting back against the Pharma-driven

psychiatric consensus that treating with SSRIs is safe and

effective, working hard to wean patient-victims as well as their

prescribers off the drugs.

She has steadily accumulated damning statistics on suicide,

homicide and hospitalisation rates among these patients in New

South Wales. More recently it has become clear that a large

percentage of people being treated with antidepressants can't

metabolise them due to common genetic mutations. Dr Lucire has

been campaigning to introduce systematic doctor education in

order to minimise promiscuous and uninformed anti-depressant

prescribing. With her complaints, findings and warnings about

lack of action, Dr Lucire has been assiduously lobbying her

colleagues, the Medical Board and the Health Care Complaints

Commission of NSW, the Adverse Drug Reactions Advisory Committee

(ADRAC) of the federal Therapeutic Goods Administration and a

clutch of ministers, both state and federal, for many years.

Most recently she has been providing redacted files on her own

extensive sample of DNA swab-tested relapsing patients suffering

from the side effects of SSRIs and polypharmacy.

And she has had one notable victory in the political arena.

Under pressure from Dr Lucire, the secretary of Health and

Ageing set up an inquiry early in 2009 into 90 of her serious

adverse drug reaction reports, which occurred mainly in normal

folk treated for stress and other vicissitudes of life and who

had become suicidal and/or homicidal on antidepressants. The

Psychiatric Drug Safety Expert Advisory Panel reported in

December last year, confirming her concerns about the

near-universality of ignorant polypharmacy and dangerous

gene-based drug-drug interactions leading to akathisia, suicide

and homicide and all the mental states preceding them.But its

recommendations are still waiting to be noticed by the NSW

Medical Board and Department of Health.

So far the Medical Board seems to have quite other ideas about

Dr Lucire's contribution to public health than the Advisory

Panel. In July 2007 one of the many patients she was trying to

save from another bout of potentially lethal akathisia killed

her own father and sister. In her view, this patient's akathisia

was initially caused by the polypharmacy which had previously

aggravated her mental condition. But this case led to Medical

Board proceedings against her. She has concerns about the

board's procedures and why she is being targeted.

At the core of her alleged delinquency are charges that she has

failed to recognise that SSRI treatment is "standard practice" -

also "best practice"; that she has "unusual beliefs (read: not

good for the professional bottom line) about the side effects of

psychotropic medication"; that she is "lacking in respect for

colleagues' diagnoses", and has been "guilty of destroying

patients" confidence in their treating doctor" (while saving

their sanity and/or lives, could we add?).

Galileo would have been familiar with this kind of stuff. What

Dr Lucire's hostile critics, like Galileo's, have not done is

respond professionally to her criticisms in scientific terms.

Could they be scared of the result? Dr Lucire continues to draw

attention to the causes of the public mental health problem,

albeit at times in a naive, didactic or exasperated manner, as

she admits herself. She has good grounds for paranoia, but she

is unwise to be forever saying that no-one takes any notice of

her (fully justified) Cassandra-like warnings. The Expert

Advisory Panel did; some fair-minded journalists do, and also a

sprinkling of academics in science based disciplines.

She is appealing the latest tribunal decision in the Supreme

Court of New South Wales backed with character references by a

Who's Who of people wise to the ways of corporate money in the

medical professions and familiar with the differences between

majority views and what is scientifically established in

psychiatry. Dr Lucire also persists in trying to stymie the

campaign currently building around the country to drastically

expand hospital and clinical services for the mentally ill.

Prominent in this campaign are Australian of the Year 2010,

Professor McGorry of Melbourne University and headspace,

and Professor Ian Hickie of the Brain and Mind Research

Institute at Sydney University and the SPHERE national

depression initiative.

McGorry is a proponent of early drug intervention to

combat youth depression. Ian Hickie is an outspoken and

genuinely concerned intervener in a wide array of debates on the

social health of Australia and Australians, most recently

concerning the fate of badly accommodated university students.

But his Brain and Mind Institute was lately discovered by The

Australian to be housing

Lifeblood, a private company helping the pharmacy

industry spend $75 million on "doctors' education". Lifeblood

has boasted on its website that SPHERE, "a mental health program

undertaken by 12,000 GPs since 1998", of which both Pfizer and

the Brain and Mind Research Institute are commercial partners,

has restored Pfizer's Zoloft to market leadership in the

anti-depressant stakes. Hickie himself was the architect of the

controversial (and Bristol Myers Squibb funded) "depression

screening tool" (a checklist of questions for GPs) used in

SPHERE.

How awkward this all must be for his institute - and for your

(and my) Sydney University, which also boasts a Pfizer/PPF Chair

of Pharmacy Management and a Pfizer Australian Chair in Clinical

Pharmacy. Professor Hickie also co-authored the Royal Australian

and New Zealand College of Psychiatrists' original (2003)

recommended guidelines for treatment of depression, whose

clarion call was: "Depression is common, serious and treatable.

It affects 1 in 25 people in any 1 month." These RANZCP

guidelines recommended that even "moderately severe" depression

should be treated with Nefazadone, a drug which was withdrawn

four months later because of fatal side effects. Very few

specific side effects or drug-drug interactions were reported in

these guidelines, which have been only cosmetically improved in

their 2009 version for the “consumer and carer”.

The RANZCP guidelines (and near identical ones around the

world) emerged from the Texas of Governor W Bush where

they became mandatory in the treatment of prisoners and public

mental patients following a lavish lobbying campaign under the

rubric of the Texas Medication Algorithm Project by Big Pharma.

According to Dr Lucire, the notion of applying algorithms or

"one size fits all" to a genetically diverse population in the

days of personalised medicine borders on obscene.

What is first and most needed in Australia's so far depressing,

big American, Pharma driven approach to depression is not more

of the same but less. Antidepressants used for anything less

then severe depression, and closely monitored, are an expensive,

ineffective (less than three per cent more effective than

placebo in clinical trials presented to the US Food and Drug

Administration for their licensing) and dangerous family of

drugs whose side effects and addictive qualities have triggered

a serious crisis in public health - not least by an explosion of

hospital beds for unrecognised side effect casualties.

The highway to massive cost savings - and effective redirection

of public spending on mental health - is to break the addiction

of psychiatrists, doctors, medical bureaucracies and patients to

the notion that there is a pill for every ill. Dr Lucire's

professional martyrdom may well continue short term. But

developments in the US suggest that her brave and brilliant

efforts in this direction, however casually and cynically

denigrated, will eventually prevail here. There will be many and

much to answer for if justice for her and the Australian victims

of the SSRI scourge is long delayed.

Posted

http://www.onlineopinion.com.au/view.asp?article=11394 & page=0

Whistleblower in Coventry: Dr Yolande Lucire and Big Pharma

By King - posted Monday, 20

December 2010

Australia lags well behind the US and Britain in facing up to

the malfeasance of multinational drug companies pushing unsafe

products. Very often Big Pharma itself has largely conjured up

the booming markets in which its dubious drugs offer expensive

treatment for dubious medical conditions.

The biggest and most lucrative scandals have been in two types

of second-generation drugs: anti-depressants or SSRIs - Prozac,

Paxil, Zoloft, etc, and "atypical" antipsychotics such as

Zyprexa, Risperdal and Seroquel which were known from their

licensing to be ineffective for the vast majority of clinical

trial subjects and up to twice as bad for inducing suicide as

antidepressants.

The corrupt drug trial and marketing practices of Big Pharma

include imaginary science (the serotonin deficiency theory of

depression), systematic suppression of lethal side effects

(akathisia - cannot-sit-down restlessness - leading to suicidal

ideation, suicide and murder) and a multi-billion dollar success

over the past generation in medicalising the ordinary ups and

downs of the human psyche.

Feeling sad? ("Moderate depression", worthy of a happy little

Zoloft rock.) Diffident? ("Social anxiety disorder", try

Aropax.) If antidepressants cured any significant number of

people there would be significantly less cost and less demand

for mental health services in Australia. Whether from inadequate

or tendentious pharmacology training, laziness, busyness, greed

driven by willed ignorance or even misplaced conviction, the

medical profession has succumbed to the cynical marketing and

the targeted blandishments of the pharmaceutical companies.

Medical and scientific journals from Nature to The

New England Journal of Medicine allowed their columns to

be infiltrated for years by blatantly dishonest research

reporting and ghost written articles commissioned in Pharma-land

but signed by distinguished professors frequently in receipt of

seven-figure research and consultancy funding. Most of these

journals do now take another tack, debunking Pharma claims and

exposing fraudulence. But many medical professional bodies are

still being subsidised beyond hope of objective dealing with the

issue of mass iatrogenesis caused by dud drugs andmultiple drug

prescribing ("polypharmacy"), and particularly with the lethal

side effects of anti-depressants.

The key drug regulator in the US - and the planet - the United

States Food and Drug Administration (US FDA) has failed to purge

the Pharma-friendly experts who have dominated its rulings up to

now. Our own Therapeutic Goods Administration obediently follows

suit, also licensing drugs largely on information provided by

their makers. But in America the going has been getting

perceptibly harder for the drug companies.

Whistleblowers, class actions and litigious state governments

confronting ballooning health costs have been taking a toll on

profits. Pfizer was recently fined $US2.3 billion for

fraudulently promoting four drugs including the "antipsychotic"

Zeldox last year. This fine is seriously denting Pfizer's bottom

(net income) line of $US8 billion, and whistleblowers, including

former Pfizer employees, collected over $US100 million for their

pains in this case - a big threat to Pharma for the future.

Although such a fine has been described in a recent British

Medical Journal as"firing 22s into the arse of a rhino"

and Pfizer has been called "too big to nail" (only a Pfizer

subsidiary pleaded guilty to criminal charges), drug companies

face a rising tide of multi-billion dollar class actions and the

prospect of new laws which could put them out of business. The

original whistleblowers who were listened to have made the key

difference in the United States. Whitaker traced the

suicide epidemic and mental health cost blow-out following the

launch of Prozac in 1988. The quiet Irishman, Healy,

exposed drug trial fakery and the vast, hidden collateral damage

of pharma's SSRI bonanza in the 1990s and later.

These two and others have engineered a paradigm shift in public

understanding, and professorial heads in receipt of undeclared

consultancy riches have started to roll at research institutes

and universities in the US, including even Harvard. According to

the New York Times, Dr ph Biederman, the pioneer of

"aggressive diagnosis and drug treatment of childhood bipolar

disorder", failed

to report most of the $1.6 million he received in pharma

funding over several years while at Harvard.

The single person who has been trying hardest to fill the

Whitaker/Healy whistleblower gap in Australia is Sydney

psychiatrist, Dr Yolande Lucire. Thirteen years ago she began to

notice alarmingly high hospital admission and suicide rates

among patients treated with SSRIs and atypical antipsychotics in

New South Wales's Greater Southern Area Health Service. Since

then she has been fighting back against the Pharma-driven

psychiatric consensus that treating with SSRIs is safe and

effective, working hard to wean patient-victims as well as their

prescribers off the drugs.

She has steadily accumulated damning statistics on suicide,

homicide and hospitalisation rates among these patients in New

South Wales. More recently it has become clear that a large

percentage of people being treated with antidepressants can't

metabolise them due to common genetic mutations. Dr Lucire has

been campaigning to introduce systematic doctor education in

order to minimise promiscuous and uninformed anti-depressant

prescribing. With her complaints, findings and warnings about

lack of action, Dr Lucire has been assiduously lobbying her

colleagues, the Medical Board and the Health Care Complaints

Commission of NSW, the Adverse Drug Reactions Advisory Committee

(ADRAC) of the federal Therapeutic Goods Administration and a

clutch of ministers, both state and federal, for many years.

Most recently she has been providing redacted files on her own

extensive sample of DNA swab-tested relapsing patients suffering

from the side effects of SSRIs and polypharmacy.

And she has had one notable victory in the political arena.

Under pressure from Dr Lucire, the secretary of Health and

Ageing set up an inquiry early in 2009 into 90 of her serious

adverse drug reaction reports, which occurred mainly in normal

folk treated for stress and other vicissitudes of life and who

had become suicidal and/or homicidal on antidepressants. The

Psychiatric Drug Safety Expert Advisory Panel reported in

December last year, confirming her concerns about the

near-universality of ignorant polypharmacy and dangerous

gene-based drug-drug interactions leading to akathisia, suicide

and homicide and all the mental states preceding them.But its

recommendations are still waiting to be noticed by the NSW

Medical Board and Department of Health.

So far the Medical Board seems to have quite other ideas about

Dr Lucire's contribution to public health than the Advisory

Panel. In July 2007 one of the many patients she was trying to

save from another bout of potentially lethal akathisia killed

her own father and sister. In her view, this patient's akathisia

was initially caused by the polypharmacy which had previously

aggravated her mental condition. But this case led to Medical

Board proceedings against her. She has concerns about the

board's procedures and why she is being targeted.

At the core of her alleged delinquency are charges that she has

failed to recognise that SSRI treatment is "standard practice" -

also "best practice"; that she has "unusual beliefs (read: not

good for the professional bottom line) about the side effects of

psychotropic medication"; that she is "lacking in respect for

colleagues' diagnoses", and has been "guilty of destroying

patients" confidence in their treating doctor" (while saving

their sanity and/or lives, could we add?).

Galileo would have been familiar with this kind of stuff. What

Dr Lucire's hostile critics, like Galileo's, have not done is

respond professionally to her criticisms in scientific terms.

Could they be scared of the result? Dr Lucire continues to draw

attention to the causes of the public mental health problem,

albeit at times in a naive, didactic or exasperated manner, as

she admits herself. She has good grounds for paranoia, but she

is unwise to be forever saying that no-one takes any notice of

her (fully justified) Cassandra-like warnings. The Expert

Advisory Panel did; some fair-minded journalists do, and also a

sprinkling of academics in science based disciplines.

She is appealing the latest tribunal decision in the Supreme

Court of New South Wales backed with character references by a

Who's Who of people wise to the ways of corporate money in the

medical professions and familiar with the differences between

majority views and what is scientifically established in

psychiatry. Dr Lucire also persists in trying to stymie the

campaign currently building around the country to drastically

expand hospital and clinical services for the mentally ill.

Prominent in this campaign are Australian of the Year 2010,

Professor McGorry of Melbourne University and headspace,

and Professor Ian Hickie of the Brain and Mind Research

Institute at Sydney University and the SPHERE national

depression initiative.

McGorry is a proponent of early drug intervention to

combat youth depression. Ian Hickie is an outspoken and

genuinely concerned intervener in a wide array of debates on the

social health of Australia and Australians, most recently

concerning the fate of badly accommodated university students.

But his Brain and Mind Institute was lately discovered by The

Australian to be housing

Lifeblood, a private company helping the pharmacy

industry spend $75 million on "doctors' education". Lifeblood

has boasted on its website that SPHERE, "a mental health program

undertaken by 12,000 GPs since 1998", of which both Pfizer and

the Brain and Mind Research Institute are commercial partners,

has restored Pfizer's Zoloft to market leadership in the

anti-depressant stakes. Hickie himself was the architect of the

controversial (and Bristol Myers Squibb funded) "depression

screening tool" (a checklist of questions for GPs) used in

SPHERE.

How awkward this all must be for his institute - and for your

(and my) Sydney University, which also boasts a Pfizer/PPF Chair

of Pharmacy Management and a Pfizer Australian Chair in Clinical

Pharmacy. Professor Hickie also co-authored the Royal Australian

and New Zealand College of Psychiatrists' original (2003)

recommended guidelines for treatment of depression, whose

clarion call was: "Depression is common, serious and treatable.

It affects 1 in 25 people in any 1 month." These RANZCP

guidelines recommended that even "moderately severe" depression

should be treated with Nefazadone, a drug which was withdrawn

four months later because of fatal side effects. Very few

specific side effects or drug-drug interactions were reported in

these guidelines, which have been only cosmetically improved in

their 2009 version for the “consumer and carer”.

The RANZCP guidelines (and near identical ones around the

world) emerged from the Texas of Governor W Bush where

they became mandatory in the treatment of prisoners and public

mental patients following a lavish lobbying campaign under the

rubric of the Texas Medication Algorithm Project by Big Pharma.

According to Dr Lucire, the notion of applying algorithms or

"one size fits all" to a genetically diverse population in the

days of personalised medicine borders on obscene.

What is first and most needed in Australia's so far depressing,

big American, Pharma driven approach to depression is not more

of the same but less. Antidepressants used for anything less

then severe depression, and closely monitored, are an expensive,

ineffective (less than three per cent more effective than

placebo in clinical trials presented to the US Food and Drug

Administration for their licensing) and dangerous family of

drugs whose side effects and addictive qualities have triggered

a serious crisis in public health - not least by an explosion of

hospital beds for unrecognised side effect casualties.

The highway to massive cost savings - and effective redirection

of public spending on mental health - is to break the addiction

of psychiatrists, doctors, medical bureaucracies and patients to

the notion that there is a pill for every ill. Dr Lucire's

professional martyrdom may well continue short term. But

developments in the US suggest that her brave and brilliant

efforts in this direction, however casually and cynically

denigrated, will eventually prevail here. There will be many and

much to answer for if justice for her and the Australian victims

of the SSRI scourge is long delayed.

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...